Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 7Sarcoma 5Other hematologic neoplasm 2Plasma cell 1Other neoplasm 1Myeloid 1

Conditions

Multiple Myeloma 207Neoplasms, Plasma Cell 73Lymphoma 71Lymphoma, Non-Hodgkin 48Leukemia, Lymphocytic, Chronic, B-Cell 47Precursor Cell Lymphoblastic Leukemia-Lymphoma 42Leukemia 37Hodgkin Disease 37Lymphoma, Follicular 36Lymphoma, Mantle-Cell 35Lymphoma, Large B-Cell, Diffuse 35Hematologic Neoplasms 34Leukemia, Myeloid, Acute 33Lymphoma, B-Cell, Marginal Zone 32Burkitt Lymphoma 32Myelodysplastic Syndromes 31Lymphoma, Large-Cell, Immunoblastic 31Myeloproliferative Disorders 26Leukemia, Myeloid, Chronic-Phase 22Leukemia, Myeloid, Accelerated Phase 22Blast Crisis 21Lymphoma, T-Cell, Cutaneous 19Leukemia, Hairy Cell 19Primary Myelofibrosis 18Waldenstrom Macroglobulinemia 17Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 17Leukemia, Myelomonocytic, Chronic 16Sezary Syndrome 15Mycosis Fungoides 15Lymphoma, Large-Cell, Anaplastic 15

Interventions

ibrutinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Multi-centric Castleman's Disease × Plasma cell × Clear all
NCT02109224 2015-08-20

Ibrutinib in Treating Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma in Patients With HIV Infection

National Cancer Institute (NCI)

Phase 1 Terminated
72 enrolled
LymphoidOther hematologic neoplasmPlasma cell

Multi-centric Castleman's Disease, Burkitt Lymphoma, Leukemia, Hairy Cell, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Multiple Myeloma, Leukemia, Lymphocytic, Chronic, B-Cell, HIV Infections, Lymphoma, Large-Cell, Immunoblastic, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Intraocular Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡